China Against Drug Resistance (CARE) Point Prevalence Study: A Tool for Evaluating Hospital Acquired Infections and Antimicrobial Prescription at Patient Bedside

Yonghong Xiao, Qiang Wang, Jing Yang, Jingping Zhang, Hongyi Lin, Wenjie Yang, Changwen Feng, Yukun Chen, Wenxiang Huang, Pascal Vincelot, Qizhi Liao, Stanley Gong, Yijun Xia, Vincent Jarlier
{"title":"China Against Drug Resistance (CARE) Point Prevalence Study: A Tool for Evaluating Hospital Acquired Infections and Antimicrobial Prescription at Patient Bedside","authors":"Yonghong Xiao, Qiang Wang, Jing Yang, Jingping Zhang, Hongyi Lin, Wenjie Yang, Changwen Feng, Yukun Chen, Wenxiang Huang, Pascal Vincelot, Qizhi Liao, Stanley Gong, Yijun Xia, Vincent Jarlier","doi":"10.2174/0118742203311447240703051016","DOIUrl":null,"url":null,"abstract":"\n \n China Against Drug Resistance (CARE) project was launched for improving antimicrobial use and infection control in Chinese hospitals. The first step was developing a Point Prevalence Survey (PPS) tool for assessing at patient bedside risk factors and rates of hospital acquired infections (HAIs) and quality indicators of antimicrobial usage and testing its workability.\n \n \n \n After a pilot phase (2016), the CARE PPS tool was deployed in 2018-9 in eight large Chinese hospitals. Each hospital selected 3-5 adult departments (intensive care, surgery, medicine). The questionnaire in English and Chinese, on paper and tablet computer, was filled out directly at the patient's bedside by local infection control teams, microbiologists, pharmacists and clinicians.\n \n \n \n The number of patients visited per day and per investigator team increased from 20-30 during the pilot phase in the first hospital to 40-50 in the eight other hospitals. The main characteristics of the 1,170 patients included (ICU 138, medicine 430, surgery 602) were: median age 60 years; Mac Cabe score 1 74.7%; catheters: central vascular 14.3%, peripheral vascular 50.9%, urinary 19.8%; surgery during stay 31.8%. HAIs prevalence was 6.3% (mainly respiratory tract, surgical-site; main bacteria: Acinetobacter, Pseudomonas, Klebsiella). 54.4% of the patients were receiving antimicrobials for therapeutical use (≈3/4 single drug): from 36% in surgery to 78.3% in ICU, mostly large spectrum beta-lactams. Examination of patient records at the bedside found the reason for the treatment (53%), treatments based on microbiological results (9.3%), and prescription reassessment (30.7%).\n \n \n \n The study showed that antimicrobial policy and HAI prevention could be improved by using Care-PPS in Chinese hospitals. Although obtained on a limited number of patients, the results demonstrated that there is room for improvement in antimicrobial policy and HAI prevention in the participating hospitals.\n","PeriodicalId":91371,"journal":{"name":"Open medicine journal","volume":"23 5","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open medicine journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118742203311447240703051016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

China Against Drug Resistance (CARE) project was launched for improving antimicrobial use and infection control in Chinese hospitals. The first step was developing a Point Prevalence Survey (PPS) tool for assessing at patient bedside risk factors and rates of hospital acquired infections (HAIs) and quality indicators of antimicrobial usage and testing its workability. After a pilot phase (2016), the CARE PPS tool was deployed in 2018-9 in eight large Chinese hospitals. Each hospital selected 3-5 adult departments (intensive care, surgery, medicine). The questionnaire in English and Chinese, on paper and tablet computer, was filled out directly at the patient's bedside by local infection control teams, microbiologists, pharmacists and clinicians. The number of patients visited per day and per investigator team increased from 20-30 during the pilot phase in the first hospital to 40-50 in the eight other hospitals. The main characteristics of the 1,170 patients included (ICU 138, medicine 430, surgery 602) were: median age 60 years; Mac Cabe score 1 74.7%; catheters: central vascular 14.3%, peripheral vascular 50.9%, urinary 19.8%; surgery during stay 31.8%. HAIs prevalence was 6.3% (mainly respiratory tract, surgical-site; main bacteria: Acinetobacter, Pseudomonas, Klebsiella). 54.4% of the patients were receiving antimicrobials for therapeutical use (≈3/4 single drug): from 36% in surgery to 78.3% in ICU, mostly large spectrum beta-lactams. Examination of patient records at the bedside found the reason for the treatment (53%), treatments based on microbiological results (9.3%), and prescription reassessment (30.7%). The study showed that antimicrobial policy and HAI prevention could be improved by using Care-PPS in Chinese hospitals. Although obtained on a limited number of patients, the results demonstrated that there is room for improvement in antimicrobial policy and HAI prevention in the participating hospitals.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中国抗耐药性(CARE)点流行率研究:评估医院感染和患者床旁抗菌药物处方的工具
中国抗耐药项目(CARE)旨在改善中国医院的抗菌药物使用和感染控制。第一步是开发一个点流行率调查(PPS)工具,用于评估患者床旁的风险因素和医院获得性感染(HAIs)率以及抗菌药物使用的质量指标,并测试其可操作性。 经过试点阶段(2016 年),CARE PPS 工具于 2018-9 年在中国 8 家大型医院部署。每家医院选择了 3-5 个成人科室(重症监护、外科、内科)。当地感染控制团队、微生物学家、药剂师和临床医生在患者床旁直接填写纸质和平板电脑中英文问卷。 在第一家医院的试点阶段,每个调查小组每天访问的患者人数为 20-30 人,而在其他八家医院则增加到 40-50 人。纳入调查的 1170 名患者(重症监护室 138 名、内科 430 名、外科 602 名)的主要特征是:中位年龄 60 岁;Mac Cabe 评分 1 74.7%;导管:中央血管 14.3%、外周血管 50.9%、泌尿系统 19.8%;住院期间手术 31.8%。HAIs 感染率为 6.3%(主要是呼吸道感染、手术部位感染;主要细菌:醋酸痤疮杆菌、假单胞菌、痢疾杆菌、痢疾杆菌、痢疾杆菌主要细菌:不动杆菌、假单胞菌、克雷伯氏菌)。54.4%的患者在接受治疗用抗菌药(≈3/4 种单一药物):从手术室的 36% 到重症监护室的 78.3%,主要是大谱β-内酰胺类药物。床旁病历检查发现了治疗原因(53%)、基于微生物学结果的治疗(9.3%)和处方再评估(30.7%)。 研究表明,在中国医院使用 Care-PPS 可以改善抗菌药物政策和 HAI 预防。虽然研究对象是有限的患者,但研究结果表明,参与研究的医院在抗菌药物政策和 HAI 预防方面仍有改进的空间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
China Against Drug Resistance (CARE) Point Prevalence Study: A Tool for Evaluating Hospital Acquired Infections and Antimicrobial Prescription at Patient Bedside CLEC4A Expression as a Prognostic Biomarker and Immunoregulator in Lung Adenocarcinoma: Insights from Immune Cell Infiltration Value of the A2DS2 Score Combined with the Neutrophil-to-lymphocyte Ratio in Predicting Acute Ischemic Stroke-associated Pneumonia Systemic Lupus Erythematosus in a Patient with Liver Cirrhosis: Case Report and Literature Review Comparing the Effectiveness and Safety of Anterior Cervical Discectomy and Fusion with Four Different Fixation Systems: A Systematic Review and Network Meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1